联合应用静脉溶栓和替罗非班治疗急性ST段抬高型心肌梗死的有效性和安全性

Dissolves the hitch jointly using the vein and treats the acute ST section for Luo Feiban to raise cardiac arrests validity and the security

目的研究急性sT段抬高型心肌梗死（STEMI）的急性冠脉综合征（ACS）患者在行尿激酶（UK）静脉溶栓的同时应用国产血小板膜糖蛋白IIb／HIa受体拮抗剂替罗非班的有效性和安全性。方法62例STEMI—ACS患者随机分为受试组（UK静脉溶栓＋替罗非班，31例）和对照组（替罗非班，31例），替罗非班疗程24—36h，入院4—6h行冠状动脉造影。结果受试组24h及30d的主要不良心脏事件（MACE）发生率明显低于对照组（3．5％比21．2％，P〈0．001）。受试组和对照组均未出现大出血，皮肤、黏膜小出血发生率为26％和21％，二组差异无统计学意义（P〉0．05），受试组梗死相关血管（IRA）再通率明显高于对照组（68％比24％）。结论联合应用UK静脉溶栓和替罗非班治疗STEMI，IRA再通率高，能进一步改善预后，且安全性好。

Objective To research acute ST section raises the cardiac arrest（ STEMI） acute crown ar- teries syndrome（ACS） patient to be an expert to good expert the urokinase（UK） the vein to dissolve bitch＇s at the same time applies the domestically produced blood platelet membrane glycoprotein Ⅱb/Ⅲ a acceptor antagonist compound for Lao Feiban（joyful Vining）the validity and the security. Methods The 62 STEMI-ACS patients divided into stochastically is tried the group（the UK vein to dissolve hitch ＋ for Luo Feiban,32 examples）and the control group（ for Luo Feiban,32 examples） ,joyful Vining treatment course 24 - 36 h,is hospitalized 4 - 6 small fashionable coronarography. Results Group 24 h and the 30 d main bad heart event （MACE） the forma- tion rate is lower than obviously the control group （3.5 % compared to 21.2, P 〈 O. 05 ）, is tried the group stem to die is related the blood vessel （IRA）passing rate to be higher than the control group obviously again （68% ： 24% ）. Conclusion Dissolves the hitch jointly using the UK vein and treats STEMI, IRA passing rate for Luo Feiban to be again high, can further improve the prognosis, and the security is good.